Skip to main content

Table 1 Distribution of the SULT1A1 rs9282861 genotypes in relation to the subject characteristics§

From: SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

  

rs9282861 genotype

Characteristics

All subjects (n = 412)

GG (n = 121)

AG (n = 194)

AA (n = 97)

Age at diagnosis, years

    

   ≤ 39

37 (9.0)

14 (37.8)

15 (40.5)

8 (21.6)

   40-49

98 (23.8)

34 (34.7)

40 (40.8)

24 (24.5)

   50-59

104 (25.2)

29 (27.9)

51 (49.0)

24 (23.1)

   60-69

65 (15.8)

16 (24.6)

36 (55.4)

13 (20.0)

   ≥ 70

108 (26.2)

28 (25.9)

52 (48.1)

28 (25.9)

T stage (UICC)†

    

   1

215 (52.2)

59 (27.4)

101 (47.0)

55 (25.6)

   2

164 (39.8)

56 (34.1)

73 (44.5)

35 (21.3)

   3

22 (5.3)

3 (13.6)

15 (68.2)

4 (18.2)

   4

11 (2.7)

3 (27.3)

5 (45.5)

3 (27.3)

Nodal status (UICC)

    

   N-

247 (60.0)

67 (27.1)

117 (47.4)

63 (25.5)

   N+

165 (40.0)

54 (32.7)

77 (46.7)

34 (20.6)

Stage (UICC)

    

   I

165 (40.0)

46 (27.9)

79 (47.9)

40 (24.2)

   II

210 (51.0)

68 (32.4)

92 (43.8)

50 (23.8)

   III

37 (9.0)

7 (18.9)

23 (62.2)

7 (18.9)

Oestrogen receptor status

    

   Positive

310 (75.2)

88 (28.4)

146 (47.1)

76 (24.5)

   Negative

89 (21.6)

28 (31.5)

45 (50.6)

16 (18.0)

   Unknown

13 (3.2)

5 (38.5)

3 (23.1)

5 (38.5)

Progesterone receptor status

    

   Positive

247 (60.0)

71 (28.7)

113 (45.7)

63 (25.5)

   Negative

150 (36.4)

45 (30.0)

76 (50.7)

29 (19.3)

   Unknown

15 (3.6)

5 (33.3)

5 (33.3)

5 (33.3)

Morphological type

    

   Ductal

268 (65.0)

75 (28.0)

132 (49.3)

61 (22.8)

   Lobular

70 (17.0)

28 (40.0)

27 (38.6)

15 (21.4)

   Other types

74 (18.0)

18 (24.3)

35 (47.3)

21 (28.4)

Adjuvant treatment

    

   Radiotherapy

243 (59.0)

74 (30.5)

110 (45.3)

59 (24.3)

   Endocrine therapy

106 (25.7)

28 (26.4)

56 (52.8)

22 (20.8)

Tamoxifen

88 (21.4)

23 (26.1)

45 (51.1)

20 (22.7)

Toremifen

17 (4.1)

5 (29.4)

11 (64.7)

1 (5.9)

Chemotherapy

80 (19.4)

34 (42.5)

31 (38.8)

15 (18.8)

Vital Status

    

   Alive

184 (44.7)

50 (27.2)

88 (47.8)

46 (25.0)

No recurrence

159 (38.6)

41 (25.8)

79 (49.7)

39 (24.5)

Recurrence of breast cancer

25 (6.1)

9 (36.0)

9 (36.0)

7 (28.0)

Death

228 (55.3)

71 (31.1)

106 (46.5)

51 (22.4)

   Breast cancer caused death

112 (27.2)

40 (35.7)

49 (43.8)

23 (20.5)

   Death with other reasons

116 (28.2)

31 (26.7)

57 (49.1)

28 (24.1)

  1. §Values in the table are number of patients (%).
  2. †UICC = International Union Against Cancer, TNM Classification of Malignant Tumours, Fourth, Fully Revised Edition
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us